LMO4 and pancreatic cancer outcomes
Author Information
Author(s): Murphy N C, Scarlett C J, Kench J G, Sum E Y M, Segara D, Colvin E K, Susanto J, Cosman P H, Lee C-S, Musgrove E A, Sutherland R L, Lindeman G J, Henshall S M, Visvader J E, Biankin A V
Primary Institution: Garvan Institute of Medical Research
Hypothesis
High LMO4 expression is associated with better survival outcomes in pancreatic ductal adenocarcinoma.
Conclusion
Patients with high LMO4 expression have a significant survival advantage after surgery, while those with low or no expression do not benefit from surgical resection.
Supporting Evidence
- High LMO4 expression was found in 83.3% of tumors in the study.
- Patients with LMO4-positive tumors had a median survival of 14.2 months after resection.
- Patients with LMO4-negative tumors had no survival advantage from surgical resection.
Takeaway
This study found that a protein called LMO4 can help doctors predict how well patients with pancreatic cancer will do after surgery.
Methodology
The study analyzed LMO4 expression in pancreatic cancer tissues from 120 patients and assessed its association with survival outcomes.
Limitations
The study's findings need validation in larger independent cohorts.
Participant Demographics
The cohort included 120 patients diagnosed with pancreatic ductal adenocarcinoma, with a mean age of 64.3 years.
Statistical Information
P-Value
0.0364
Confidence Interval
(0.297–0.961)
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website